Endo acquires Canadian spec pharma Paladin for $Cdn1.5bn
Executive Summary
Endo Health Solutions Inc. acquired publicly traded Canadian spec pharma Paladin Labs Inc. for $Cdn1.5bn ($1.5bn). New Endo, a holding company based in Ireland, was formed, and each current Endo share is equivalent to one New Endo share. New Endo will own the combined Endo/Paladin and trade on Nasdaq, with Endo stockholders controlling 77.5% of the combined company, and Paladin the rest (because of this structure, the transaction isn’t expected to be taxable to Endo’s US shareholders, but will be taxable to Paladin’s in Canada). Paladin retains its name, current management, and Montreal headquarters.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice